Physician profile
Nora E Martinez
NPI 1902815970
$1,659.08
in general payments reported to CMS, 2019-2025
14 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $101 · 2023: $20.54 · 2024: $479 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $296.28 | 2022-2025 | |
| Akebia Therapeutics INC | $242.21 | 2021-2025 | Vafseo |
| Abbott Laboratories | $233.70 | 2021-2024 | Freestyle Libre |
| Alexion Pharmaceuticals, INC. | $121.16 | 2024 | |
| Sanofi-Aventis U.S. LLC | $120.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $119.94 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $118.93 | 2021 | |
| Averitas Pharma INC. | $115.42 | 2024 | Qutenza |
| Lexicon Pharmaceuticals, INC. | $110.17 | 2024 | Inpefa |
| Ascensia Diabetes Care US INC. | $103.67 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.49 | 2021 | |
| Fresenius USA Marketing, INC. | $20.54 | 2023 | Velphoro |
| Pacira Pharmaceuticals Incorporated | $17.44 | 2022 | |
| Cipher Pharmaceuticals US LLC | $16.52 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.